ADA-话题@MedSci

#ADA#

386篇内容 | 2769人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1264703, encodeId=2a521264e03ec, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADA 2019：间歇性断食可能有助于糖尿病的控制, objectType=article, longId=167928, objectId=486716e9281f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=486716e9281f, replyNumber=0, likeNumber=52, createdTime=2019-06-11, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=486716e9281f, moduleTitle=ADA 2019：间歇性断食可能有助于糖尿病的控制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=486716e9281f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264702, encodeId=777b1264e0275, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果, objectType=article, longId=167491, objectId=1e2a16e491c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e2a16e491c8, replyNumber=0, likeNumber=70, createdTime=2019-06-03, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e2a16e491c8, moduleTitle=The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e2a16e491c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264701, encodeId=40541264e0152, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Lancet：Upadacitinib单药治疗甲氨蝶呤应答不充分的类风湿性关节炎, objectType=article, longId=167017, objectId=ba5d16e017b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba5d16e017b4, replyNumber=0, likeNumber=55, createdTime=2019-05-29, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba5d16e017b4, moduleTitle=Lancet：Upadacitinib单药治疗甲氨蝶呤应答不充分的类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba5d16e017b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264700, encodeId=01e11264e00f7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Lancet：Upadacitinib单药是否可替代甲氨蝶呤治疗类风湿性关节炎？, objectType=article, longId=166786, objectId=cc2b166e864d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc2b166e864d, replyNumber=0, likeNumber=75, createdTime=2019-05-27, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc2b166e864d, moduleTitle=Lancet：Upadacitinib单药是否可替代甲氨蝶呤治疗类风湿性关节炎？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc2b166e864d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264699, encodeId=3bc81264699f6, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Ada助力长三角全科医生, objectType=article, longId=166510, objectId=c50216651066, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c50216651066, replyNumber=0, likeNumber=136, createdTime=2019-05-22, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c50216651066, moduleTitle=Ada助力长三角全科医生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c50216651066)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264698, encodeId=7ed81264698ef, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=糖尿病人怎么吃？ADA官方饮食“泌”籍来了！, objectType=article, longId=165624, objectId=6f4e1656240e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f4e1656240e, replyNumber=0, likeNumber=81, createdTime=2019-05-09, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f4e1656240e, moduleTitle=糖尿病人怎么吃？ADA官方饮食“泌”籍来了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f4e1656240e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264697, encodeId=e974126469e02, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Diabetes Care：糖尿病个体化饮食计划——ADA的全新建议, objectType=article, longId=165324, objectId=879a165324be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=879a165324be, replyNumber=0, likeNumber=82, createdTime=2019-05-05, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=879a165324be, moduleTitle=Diabetes Care：糖尿病个体化饮食计划——ADA的全新建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=879a165324be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264696, encodeId=1f2112646966d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Blood：腺苷脱氨酶2缺陷病（DADA2）的发病机制！, objectType=article, longId=165005, objectId=a1a71650053d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1a71650053d, replyNumber=0, likeNumber=92, createdTime=2019-04-27, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1a71650053d, moduleTitle=Blood：腺苷脱氨酶2缺陷病（DADA2）的发病机制！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1a71650053d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264695, encodeId=fde2126469538, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Tissue Eng Regen Med：D-RADA16-RGD增强纳米羟基磷灰石/聚酰胺66三元生物材料用于骨形成, objectType=article, longId=164940, objectId=c994164940be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c994164940be, replyNumber=0, likeNumber=70, createdTime=2019-04-26, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c994164940be, moduleTitle=Tissue Eng Regen Med：D-RADA16-RGD增强纳米羟基磷灰石/聚酰胺66三元生物材料用于骨形成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c994164940be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264694, encodeId=88521264694a7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=JACC：年轻Brugada综合征患者的临床特征研究, objectType=article, longId=164566, objectId=3297164566f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3297164566f3, replyNumber=0, likeNumber=86, createdTime=2019-04-21, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3297164566f3, moduleTitle=JACC：年轻Brugada综合征患者的临床特征研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3297164566f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264693, encodeId=c6081264693f5, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=由于毒副作用，欧洲药品管理局建议限制Lemtrada在多发性硬化症中的使用, objectType=article, longId=164344, objectId=ad231643441f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad231643441f, replyNumber=0, likeNumber=56, createdTime=2019-04-17, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad231643441f, moduleTitle=由于毒副作用，欧洲药品管理局建议限制Lemtrada在多发性硬化症中的使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad231643441f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264692, encodeId=846112646920c, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Mirada Medical投入600万英镑开发基于人工智能的成像软件，助力肿瘤放射治疗, objectType=article, longId=163901, objectId=1e13163901a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e13163901a1, replyNumber=0, likeNumber=51, createdTime=2019-04-10, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e13163901a1, moduleTitle=Mirada Medical投入600万英镑开发基于人工智能的成像软件，助力肿瘤放射治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e13163901a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264691, encodeId=23881264691a7, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=SynCardia晋升Don Webber为CEO并任命Peter Spadaro为总裁兼CCO, objectType=article, longId=163679, objectId=26281636e908, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26281636e908, replyNumber=0, likeNumber=103, createdTime=2019-04-06, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26281636e908, moduleTitle=SynCardia晋升Don Webber为CEO并任命Peter Spadaro为总裁兼CCO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26281636e908)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264690, encodeId=724a126469054, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=DIABETOLOGIA：Tetraspanin 7自身抗体可预测LADA患者β细胞功能的进行性下降？, objectType=article, longId=163570, objectId=f2011635e0e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2011635e0e8, replyNumber=0, likeNumber=94, createdTime=2019-04-05, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2011635e0e8, moduleTitle=DIABETOLOGIA：Tetraspanin 7自身抗体可预测LADA患者β细胞功能的进行性下降？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2011635e0e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264689, encodeId=df1d1264689c6, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Ocul Immunol Inflamm：Vogt-Koyanagi-Harada（VKH）疾病中TGR5的表达下降, objectType=article, longId=161459, objectId=ddc616145941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddc616145941, replyNumber=0, likeNumber=75, createdTime=2019-03-02, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddc616145941, moduleTitle=Ocul Immunol Inflamm：Vogt-Koyanagi-Harada（VKH）疾病中TGR5的表达下降, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddc616145941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264688, encodeId=69b612646885e, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=基因疗法OTL-101治疗ADA-SCID的可行性, objectType=article, longId=160998, objectId=65be1609988b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65be1609988b, replyNumber=0, likeNumber=90, createdTime=2019-02-26, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65be1609988b, moduleTitle=基因疗法OTL-101治疗ADA-SCID的可行性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65be1609988b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264687, encodeId=67eb126468eec, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请, objectType=article, longId=160893, objectId=8353160893a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8353160893a6, replyNumber=0, likeNumber=69, createdTime=2019-02-25, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8353160893a6, moduleTitle=美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8353160893a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264686, encodeId=de0c12646863b, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=2019年ADA糖尿病医学诊疗标准解读, objectType=article, longId=159996, objectId=3ba715999661, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ba715999661, replyNumber=0, likeNumber=23, createdTime=2019-02-15, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ba715999661, moduleTitle=2019年ADA糖尿病医学诊疗标准解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ba715999661)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264685, encodeId=073a1264685a6, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=NEJM：Omadacycline治疗急性细菌性皮肤和皮肤结构感染, objectType=article, longId=159831, objectId=c54515983113, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c54515983113, replyNumber=0, likeNumber=106, createdTime=2019-02-14, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c54515983113, moduleTitle=NEJM：Omadacycline治疗急性细菌性皮肤和皮肤结构感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c54515983113)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264684, encodeId=6d2e1264684cc, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=NEJM：Omadacycline治疗社区获得性细菌性肺炎, objectType=article, longId=159830, objectId=f247159830a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f247159830a2, replyNumber=0, likeNumber=83, createdTime=2019-02-14, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f247159830a2, moduleTitle=NEJM：Omadacycline治疗社区获得性细菌性肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f247159830a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ADA

2020-05-29

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADA 2019：间歇性断食可能有助于糖尿病的控制

2019-06-11

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果

2019-06-03

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Lancet：Upadacitinib单药治疗甲氨蝶呤应答不充分的类风湿性关节炎

2019-05-29

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Lancet：Upadacitinib单药是否可替代甲氨蝶呤治疗类风湿性关节炎？

2019-05-27

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Ada助力长三角全科医生

2019-05-22

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

糖尿病人怎么吃？ADA官方饮食“泌”籍来了！

2019-05-09

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Diabetes Care：糖尿病个体化饮食计划——ADA的全新建议

2019-05-05

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Blood：腺苷脱氨酶2缺陷病（DADA2）的发病机制！

2019-04-27

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Tissue Eng Regen Med：D-RADA16-RGD增强纳米羟基磷灰石/聚酰胺66三元生物材料用于骨形成

2019-04-26

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

JACC：年轻Brugada综合征患者的临床特征研究

2019-04-21

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

由于毒副作用，欧洲药品管理局建议限制Lemtrada在多发性硬化症中的使用

2019-04-17

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Mirada Medical投入600万英镑开发基于人工智能的成像软件，助力肿瘤放射治疗

2019-04-10

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

SynCardia晋升Don Webber为CEO并任命Peter Spadaro为总裁兼CCO

2019-04-06

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

DIABETOLOGIA：Tetraspanin 7自身抗体可预测LADA患者β细胞功能的进行性下降？

2019-04-05

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Ocul Immunol Inflamm：Vogt-Koyanagi-Harada（VKH）疾病中TGR5的表达下降

2019-03-02

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

基因疗法OTL-101治疗ADA-SCID的可行性

2019-02-26

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

美国FDA接受了Upadacitinib治疗中度至重度类风湿性关节炎的优先审查新药申请

2019-02-25

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

2019年ADA糖尿病医学诊疗标准解读

2019-02-15

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

NEJM：Omadacycline治疗急性细菌性皮肤和皮肤结构感染

2019-02-14

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

NEJM：Omadacycline治疗社区获得性细菌性肺炎

2019-02-14

科室
- - 订阅+
  - 更多科室
工具
服务